SCHEMBL3381007

SCHEMBL3381007

CCC(CO)NC(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.57
ALDH1A1 P00352 1/20 0.57
RAB9A P51151 1/20 0.57
HPGD P15428 2/20 0.54
CTRB1 P17538 3/20 0.53
CTSG P08311 2/20 0.51
PRSS1 P07477 1/20 0.51
CMA1 P23946 1/20 0.51
ROCK2 O75116 1/20 0.50
RPS6KA5 O75582 1/20 0.50
RPS6KA4 O75676 1/20 0.50
PRKACA P17612 1/20 0.50
MAPK1 P28482 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
IRAK1 P51617 1/20 0.50
PRKX P51817 1/20 0.50
ROCK1 Q13464 1/20 0.50
PRKG1 Q13976 1/20 0.50
PKN2 Q16513 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10358851 1.00 HTT (0.57) HTTALDH1A1RAB9AHPGDCTRB1
SCHEMBL15146792 0.91 HTT (0.68) HTTALDH1A1RAB9AHPGDCTRB1
SCHEMBL6342085 0.89 CTRB1 (0.59) ALDH1A1RAB9AHPGDCTRB1CTSG
SCHEMBL4730512 0.84 KMT2A (0.64) ALDH1A1RAB9ALMNAPOLB
SCHEMBL23280913 0.84 HTT (0.56) HTTALDH1A1RAB9AHPGDCTRB1
SCHEMBL7223871 0.84 TAS1R3 (0.63) HTTALDH1A1RAB9AHPGDCTRB1
SCHEMBL12947869 0.84 HTT (0.60) HTTALDH1A1RAB9AHPGDHDAC4
SCHEMBL14079707 0.84 HTT (0.60) HTTALDH1A1RAB9AHPGDHDAC4
SCHEMBL11018467 0.84 HTT (0.60) HTTALDH1A1RAB9AHPGDCTRB1
SCHEMBL8805810 0.83 MMP2 (0.56) ALDH1A1RAB9AHPGDCTRB1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017144393-A1 2-SUBSTITUTED 5-(PHENYL)-1,2-DIHYDRO-3H-3-BENZAZEPINE-3-CARBOXAMIDE DERIVATIVES AS BRD4 INHIBITORS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-31 WO disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
US-5310911-A Chiral synthesis for producing 1-azabicyclo(2.2.1)heptane-3-carboxylates COTTRELL I F 1994-05-10 US disclosed
US-5124460-A Enantioselective synthesis of 3-substituted 1-azabicyclo (2.2.1)heptanes MERCK SHARP & DOHME LTD. (GB) 1992-06-23 US disclosed
US-5104989-A Chiral synthesis for producing 1-azabicyclo[2.2.1] heptane-3-carboxylates MERCK SHARP & DOHME LTD. (GB) 1992-04-14 US disclosed
EP-0456310-A2 Enantioselective synthesis of 3-substituted 1-azabicyclo [2.2.1]heptanes MERCK SHARP & DOHME LTD. (GB) 1991-11-13 EP disclosed
EP-0398616-A2 Chiral synthesis for producing 1-azabicyclo[2.2.1]heptane-3-carboxylates MERCK SHARP & DOHME LTD. (GB) 1990-11-22 EP disclosed
EP-0398617-A2 Process for resolving 1-azabicyclo [2.2.1]heptane-3-carboxylates MERCK SHARP & DOHME LTD. (GB) 1990-11-22 EP disclosed
US-3953512-A Process for manufacturing 2-aminobutanol POLSKA AKADEMIA NAUK INSTYTUT CHEMII ORGANICZNEJ (PO) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 HTT 2305/4885ALDH1A1 1360/4885RAB9A 1923/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 HTT 2035/4885ALDH1A1 3795/4885RAB9A 3852/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 HTT 2305/4885ALDH1A1 1360/4885RAB9A 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.